Welcome to our dedicated page for Cumberland Pharmaceuticals news (Ticker: CPIX), a resource for investors and traders seeking the latest updates and insights on Cumberland Pharmaceuticals stock.
Cumberland Pharmaceuticals Inc. develops, acquires and commercializes branded prescription pharmaceutical products for hospital acute care, gastroenterology and oncology markets. Company news commonly covers operating results, product-portfolio updates and regulatory developments for FDA-approved brands such as Caldolor, Sancuso and Vaprisol.
Recurring updates also address Caldolor indication activity, Sancuso educational and commercial resources, and clinical or regulatory disclosures tied to Cumberland's ifetroban programs in systemic sclerosis, Duchenne muscular dystrophy-associated cardiomyopathy and idiopathic pulmonary fibrosis. Capital-structure items, material agreements and shareholder voting matters appear alongside the company's financial and portfolio updates.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) reported a 17% increase in net revenues for 2022, totaling $42 million, and achieved $8 million in cash flow. The company acquired Sancuso®, enhancing its oncology product lineup. In Q4 2022, net revenues reached $9.1 million, with Sancuso® contributing $2.4 million. Operating expenses were $47.7 million, up from $43.7 million in 2021. Cumberland moved its headquarters to Nashville, supporting growth and collaboration with Vanderbilt University. The company continues ongoing clinical development for ifetroban in severe diseases, while partnerships for international product launches signify growth potential.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) will release its annual financial results for 2022 on March 7, 2023, after market close. A conference call to discuss these results is scheduled for 4:30 p.m. Eastern Time on the same day. Interested parties can register for the call through the provided link. Cumberland focuses on delivering high-quality prescription brands across various therapeutic areas, including hospital acute care and oncology. The company's portfolio includes several FDA-approved products, such as Acetadote® and Vibativ®. Additionally, Cumberland is advancing Phase II clinical programs assessing its ifetroban candidate for several diseases.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) reported a strong third quarter in 2022, with revenues of $11.4 million, reflecting a 41% increase from the previous year. Year-to-date revenues reached $33 million, a 19% increase compared to 2021. The company attributed growth to initial sales from its newly acquired product, Sancuso. Operating expenses rose to $11.7 million, resulting in a net loss of $0.4 million, improved from last year's loss of $1.1 million. Cash flow from operations increased by 28% to $5.6 million. Total assets stood at $91 million.